LDL apheresis in clinical practice: Long-term treatment of severe hyperlipidemia

Therapeutic Apheresis

Volumn 1, Issue 1, 1997, Pages 49-54

  Bambauer, R ^a,b   Schiel, R ^a   Latza, R ^a   Klinkmann, J ^a   Schneidewind, J M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE   (Germany)

Author keywords

Coronary heart disease; Familial hypercholesterolemia; Low density lipoprotein apheresis

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 2; INSTRUMENTATION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; STATISTICS; TIME; TREATMENT OUTCOME;

ADULT; BLOOD COMPONENT REMOVAL; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031061208     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1997.tb00013.x     Document Type: Article

References (44)

1. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience). Am J Cardiovasc 1992;70:733-7.
2. Brown BG, Albers JJ, Fisher LD, Schaeter SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B (FATS). N Engl J Med 1990;323:1289-98.
3. Hjermann I, Holme I, Leven P. Oslo diet study and antismoking trial. Results after 102 months. Am J Med 1986;80:701-11.
4. Huttunen JK, Manninen V, Mänttäri M, Koskinen P, Romo M, Tenkanen L, Heinonen OP, Frick MH. The Helsinki heart study: Central Findings and clinical implications. Ann Med 1991;23:155-9.
5. Kannel WB, Castelli WP, Gordon T, McNamanra PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971;74:1-12.
6. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
7. Wannamethee G, Shaper AG, Whincup PH, Walker M. Low serum cholesterol concentrations and mortality in middle aged British men. Br Med J 1995;311:409-13.
8. McGill HC. Persistent problems in the pathogenesis of atherosclerosis. Atherosclerosis 1984;4:443-51.
9. Brett AS. Treating hypercholesterolemia: How should practicing physicians interpret the published data for patients? N Engl J Med 1989;321:676-80.
10. Laaf A. Management of hypercholesterolemia: Are preventive interventions advisable? N Engl J Med 1989;321:680-4.
11. Recommendations of the European Atherosclerosis Society prepared by the international task force for prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-56.
12. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br Med J 1993;306:1313-8.
13. Epstein FH. Beyond cholesterol. N Engl J Med 1989;320: 915-24.
14. Stein Y, Stein O. Lipoproteins, cells and atheroma formation. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease-3, 3rd International Symposium Munich 1990. Basel, Switzerland: Karger, 1992:9-16.
15. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
16. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
17. Levine GN, Keancy JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
18. Zimetbaum P, Frisham WH, Ooi WL, Derman MP, Aronson M, Gidez LI, Eder HA. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: The Bronx Aging Study. Arterioscler Thromb 1992;12:416-23.
19. LaRosa JC. Treatment of lipoproteins in elderly. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease-4, 4th International Symposium Munich 1992. Basel, Switzerland: Karger, 1993:51-6.
20. Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL apheresis on serum concentrations of human lipoprotein (a): Kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989;19:235-40.
21. Bambauer R, Keller HE, Schiel R. Three years experience with the liposorber system in hypercholesterolemia. In: Agishi T, Kawamura A, Mishima A, eds. Therapeutic plasmapheresis (XII). Utrecht and Tokyo: VSP, 1993.
22. Bambauer R, Keller HE, Latza R, Schiel R. LDL apheresis in hypercholesterolemia with the liposorber system and the immunoadsorption (Abstract). Artif Organs 1994;18:121.
23. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Diensenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D and The HELP-Study Group. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
24. Bambauer R, Schiel R, Keller HE, Latza R. LDL apheresis in two patients with extremely elevated lipoprotein(a) levels. Int J Artif Organs 1995;18:286-90.
25. Schiel R, Bambauer R, Müller UA. Treatment of severe hyperlipidemia: Lipid-lowering drugs versus low density lipoprotein-apheresis (Abstract). Eur Heart J Abstr Suppl 1995; 16:230.
26. Schiel R, Bambauer R, Müller UA. Four years' treatment of patients with severe hyperlipidemia-lipid lowering drugs versus LDL apheresis. Int J Artif Organs 1995;18:5-12.
27. Study Group European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77-88.
28. Rose GA, Blackburn H. Cardiovascular survey methods. WHO-Monogr Ser 1968;56:137-54.
29. Cook DG, Shaper AG, McFarlane PW. Using the WHO (Rose) angina questionnaire in cardiovascular epidemiological studies. Int J Epidemiol 1989;18:607-13.
30. World Health Organization Expert Committee. Second report on diabetes mellitus. World Health Organization Technical Report series No. 646. Geneva, Switzerland, 1980.
31. Apstein CS, Zilversmith DB, Lees RS, George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978;31:105-15.
32. Agishi T, Wood W, Gordon B. LDL apheresis using the Liposorber® LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr Ther Res 1994;55:879-904.
33. Bosch T, Seidel D, Gurland HJ. Efficacy of lipid apheresis: Definitions and influencing factors. Int J Artif Organs 1995; 18:210-5.
34. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
35. Smith GD, Shipley MJ, Marmot MG, Rose GR. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992;267:70-6.
36. Galle J, Bassenge E. Influence of low density lipoproteins (LDL) on the reactivity of atherosclerotic arteries. Z Kardiol 1991;80:Suppl 9, 15-20.
37. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
38. Rosengren A, Wilhelmsen L, Ericksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248-51.
39. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991;115:209-18.
40. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a) lipoprotein is an independent discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994;154:801-6.
41. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246:904-10.
42. Kostner GM, Krempler F. Lipoprotein(a). Curr Opin Lipidol 1992;3:279-84.
43. Scanu AM, Fless GM. Lipoprotein(a). Heteterogenecity and biological relevance. J Clin Invest 1990;85:1709-50.
44. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolaemia regression study: A randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.